AstraZeneca showcases oncology progress

pharmafield logo - pharma news

AstraZeneca and its global biologics research and development arm, MedImmune, are to provide an update on their oncology pipeline at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA.

New data demonstrating the strength and versatility of AstraZeneca’s line of DNA damage response (DDR) medicines in multiple types of cancer will be presented at the meeting on 3 to 7 June 2016. 

In addition, new data will highlight the momentum behind AstraZeneca’s immuno-oncology programmes, and showcase small-molecule developments including Tagrisso (osimertinib) in leptomeningeal (brain) disease and the highly-selective Bruton’s tyrosine kinase (BTK) inhibitor, acalabrutinib, in chronic lymphocytic leukaemia.

AstraZeneca is developing a comprehensive pipeline of compounds that target molecular pathways across the DDR system. These include the PARP inhibitor Lynparza (olaparib); Wee1 inhibitor AZD1775, ATM inhibitor AZD0156; ATR inhibitor AZD6738, and Aurora B Kinase inhibitor AZD2811. These compounds act on different cell-cycle points to prevent tumour cells from reproducing.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “Oncology is a strategic priority for AstraZeneca because of the potential of our broad pipeline to offer transformational therapies in cancer care. At ASCO, we will update on our next-generation portfolio focusing on DNA damage response as a breakthrough paradigm in cancer treatment, including new long-term overall survival data for Lynparza. Our increased commitment to DDR therapies complements developments in our exciting immuno-oncology pipeline, from which we are expecting clinical results over the coming year.”